Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Dec;36(12):2681–2685. doi: 10.1128/aac.36.12.2681

Saperconazole therapy in a rabbit model of invasive aspergillosis.

T F Patterson 1, D George 1, P Miniter 1, V T Andriole 1
PMCID: PMC245528  PMID: 1482137

Abstract

The efficacy of orally and intravenously administered saperconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis and compared with that of amphotericin B. Oral saperconazole at dosages of 5, 10, and 15 mg/kg of body weight per day improved survival compared with that of controls. In addition, saperconazole at 10 and 15 mg/kg/day reduced the tissue burden and reduced levels of circulating antigen, which correlated with increasing dosages of saperconazole. Intravenous saperconazole produced levels in serum more than 10-fold that of oral therapy. Intravenous saperconazole not only improved survival and reduced antigen levels but also significantly eradicated A. fumigatus from tissues compared with those of controls and was as effective as amphotericin B in these studies. Saperconazole was effective in the treatment of experimental invasive aspergillosis and demonstrates the potential of the newer azoles in therapy for invasive aspergillosis.

Full text

PDF
2681

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):413–437. doi: 10.1007/BF01964057. [DOI] [PubMed] [Google Scholar]
  2. Denning D. W., Hanson L. H., Perlman A. M., Stevens D. A. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992 Jan;15(1):21–34. doi: 10.1016/0732-8893(92)90053-v. [DOI] [PubMed] [Google Scholar]
  3. Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
  4. Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
  5. Graybill J. R., Kaster S. R. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis. 1984 Feb;129(2):292–295. [PubMed] [Google Scholar]
  6. Graybill J. R. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. doi: 10.1007/BF01964056. [DOI] [PubMed] [Google Scholar]
  7. Hostetler J. S., Hanson L. H., Stevens D. A. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1992 Feb;36(2):477–480. doi: 10.1128/aac.36.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Patterson T. F., George D., Ingersoll R., Miniter P., Andriole V. T. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother. 1991 Oct;35(10):1985–1988. doi: 10.1128/aac.35.10.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Patterson T. F., George D., Miniter P., Andriole V. T. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis. 1991 Sep;164(3):575–580. doi: 10.1093/infdis/164.3.575. [DOI] [PubMed] [Google Scholar]
  10. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  11. Patterson T. F., Miniter P., Ryan J. L., Andriole V. T. Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis. 1988 Aug;158(2):415–422. doi: 10.1093/infdis/158.2.415. [DOI] [PubMed] [Google Scholar]
  12. Sabetta J. R., Miniter P., Andriole V. T. The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infect Dis. 1985 Nov;152(5):946–953. doi: 10.1093/infdis/152.5.946. [DOI] [PubMed] [Google Scholar]
  13. Van Cutsem J., Van Gerven F., Janssen P. A. Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother. 1989 Dec;33(12):2063–2068. doi: 10.1128/aac.33.12.2063. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES